Department of Urology, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
J Urol. 2010 May;183(5):2029-35. doi: 10.1016/j.juro.2009.12.090. Epub 2010 Mar 19.
Since renal cell carcinoma is considered an immunogenic tumor, testing therapeutic strategies has been impeded by the lack of relevant tumor models in immunocompetent animals. Recent advances in bioluminescence imaging permit sensitive in vivo detection and quantification of cells emitting light. Thus, we established bioluminescent rat renal cell carcinoma cell lines for immunocompetent rats.
The rat renal cell carcinoma cell line ACI-RCC stemming from chemically induced renal cell carcinoma in syngeneic ACI rats was stably transfected with a recombinant retroviral vector encoding luciferase genes derived from fireflies (ACI-RCC-ffLuc) or click beetles (ACI-RCC-cbLuc). Cell line growth patterns were characterized by bioluminescence imaging.
Linear correlations noted observed between cell number and photon counts in each cell type. ACI-RCC-cbLuc emitted light about 500-fold higher than ACI-RCC-ffLuc. When transplanted subcutaneously, only ACI-RCC-ffLuc grew, possibly because of less antigenicity. ACI-RCC-ffLuc photon emission correlated significantly with subcutaneous tumor size. Orthotopic tumor growth and subsequent metastatic spread were monitored with time by increased photon intensity on bioluminescence imaging. Based on ACI-RCC-cbLuc bioluminescent intensity the in vitro screening test allowed the identification of several anticancer agents, including molecules related to human renal cell carcinoma progression.
The new in vivo rat renal cell carcinoma model with luciferase labeled tumor cells allowed us to monitor tumor growth noninvasively and semiquantitatively by bioluminescence imaging. This model system coupled with in vitro screening permits precise evaluation of tumor behavior in intact animals and determination of the therapeutic efficacy of anticancer agents for renal cell carcinoma.
由于肾细胞癌被认为是一种免疫原性肿瘤,因此缺乏免疫活性动物中的相关肿瘤模型,这阻碍了对治疗策略的测试。生物发光成像的最新进展允许对发光细胞进行敏感的体内检测和定量。因此,我们为免疫活性大鼠建立了生物发光大鼠肾癌细胞系。
源自同基因 ACI 大鼠化学诱导的肾细胞癌的大鼠肾癌细胞系 ACI-RCC 通过稳定转染编码来自萤火虫(ACI-RCC-ffLuc)或叩头虫(ACI-RCC-cbLuc)的荧光素酶基因的重组逆转录病毒载体进行转染。通过生物发光成像对细胞系生长模式进行了特征描述。
在每种细胞类型中,观察到细胞数量与光子计数之间存在线性相关性。ACI-RCC-cbLuc 发射的光比 ACI-RCC-ffLuc 高约 500 倍。当皮下移植时,只有 ACI-RCC-ffLuc 生长,这可能是因为抗原性较低。ACI-RCC-ffLuc 光子发射与皮下肿瘤大小显著相关。通过生物发光成像,随着时间的推移,监测到肿瘤的原位生长和随后的转移扩散,光子强度增加。基于 ACI-RCC-cbLuc 生物发光强度,体外筛选试验能够鉴定出几种抗癌药物,包括与人类肾细胞癌进展相关的分子。
带有荧光素酶标记肿瘤细胞的新型体内大鼠肾细胞癌模型允许我们通过生物发光成像非侵入性和半定量地监测肿瘤生长。该模型系统与体外筛选相结合,允许在完整动物中精确评估肿瘤行为,并确定用于肾细胞癌的抗癌药物的治疗效果。